Grants and Contracts Details
Description
This pilot study will collect clinical and pre-clinical data to consider C5aR1 levels as a putative biomarker/mediator and a putative therapeutic target in progression of PSD compared to control patients. Ischemic stroke is a leading cause of death and disability, affecting 3% of the adult US population. It is often associated with long-term physical and neuropsychological consequences. The most frequent and serious neuropsychiatric consequence is post-stroke depression (PSD), for which age is the primary risk factor, with a prevalence rate ranging from 25 to 79%. PSD remains underrecognized and poorly treated. Promising therapeutic candidates in acute and chronic animal stroke models have failed to translate into new clinical therapeutics due, in part, to the lack of understanding of the complex cellular interactions that occur in the human stroke microenvironment. There is a critical need for studies that are designed to determine the role of C5aR1 in PSD in order to identify novel therapeutic targets. Our long-term goal is to define the functional role for C5aR1 signaling in PSD, which will establish a mechanistic framework to advance the development of immuno-modulatory therapeutics to enhance patient outcomes. PMX205 is a potent and selective C5aR1 non-competitive inhibitor that crosses the blood-brain barrier (BBB) and has anti-inflammatory properties that improve outcomes in ischemic injuries. PMX205 is proven safe in human clinical trials for autoimmune diseases and is currently in Phase I clinical trials for Alzheimer's disease. In the proposed study we will explore the role of C5aR1 after stroke in humans and rats.
Status | Finished |
---|---|
Effective start/end date | 9/26/23 → 5/31/25 |
Funding
- University of Kentucky Neuroscience Research Priority Area: $25,000.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.